Background-Dose limiting acute toxicity from chemoradiation for pancreatic cancer occurs in 15%-20% of patients treated with post-operative adjuvant therapy. Reported here is a pilot study using chronomodulated infusional 5-fluorouracil (5-FU) chemoradiation (CIC) for pancreatic cancer, a treatment designed to reduce normal tissue toxicity and maintain efficacy, with specific evaluation of acute and late morbidity, patterns of disease progression, and survival.
Introduction
Chemoradiation using 5-fluorouracil (5-FU) and external beam irradiation has been a mainstay in the treatment of patients with locally advanced or unresectable pancreatic cancer [12, 13, 19, 20] and in the adjuvant setting [6, 9] . Upper abdominal irradiation is limited by late toxicity including radiation fibrosis, fistula, perforation, and functional damage to the intestinal mucosa [19, 27] . This concept is based on the pattern of dose administration (fractionation), the types and volumes of tissues treated (stomach, small intestine, liver), and the total irradiation dose. For upper gastrointestinal sites the therapeutic window can be widened by CT guided treatment planning [5] and more recently with use of new targeting techniques with non-coplanar beams [15, 25] or gated radiotherapy [Varian Corporation, personal communication 1999] . These technical approaches allow for a tighter dose envelope around the tumor while spreading the transit dose into adjacent structures in order to spare late morbidity.
Chemoradiation, in contrast to conventional irradiation, is a form of accelerated treatment that can magnify acute toxicity because of simultaneous treatment [14, 17, 18] . Increased dose intensity with chemoradiation, which incorporates systemic therapy, should be considered distinct from the higher physical dose intensity achieved locally with irradiation alone. We report here on chronomodulated chemoradiation that is designed to spare acute morbidity by manipulating temporal dose density of the systemically administered chemotherapy. The rationale for chronomodulated 5-FU administration is based on the cytokinetics of the aero-digestive mucosa and the chrono-pharmacology of 5-FU metabolism [2, 4] . Nighttime administration of 5-FU creates an advantage for using temporally dose dense 5-FU because of lowered acute toxicity in the GI tract [10] . Chronomodulated infusional 5-FU chemoradiation has been used for pelvic chemoradiation in the treatment of advanced rectal adenocarcinoma and showed remarkably low acute toxicity and excellent tumor control [11] . Reported here is our pilot approach using infusional 5-FU chronomodulated chemoradiation for patients with an upper gastrointestinal cancer site. low basal infusion rate of 0.2 ml/h for 16 hours followed by an eighthour escalating/de-escalating infusion peaking at 10 p.m Approximately 87% of the 5-FU dose is delivered during the eight-hour peak phase, and 13% of the dose is delivered over the remaining 16 hours with a portable, programmable pump (Abbot AIM PLUS). The 5-FU is infused into a peripherally inserted central intravenous catheter (PICC line) placed under fluoroscopic guidance The radiotherapy portals were all planned with CT guidance (Picker AcQSsim), and all patients were treated with four-fields (anteriorposterior and lateral opposed portals) with an arms-up technique. The median field size was 110 cm 2 . The daily fractionation was 1.8 Gy per day with a total median dose of 50 4 Gy (range 50 4-59.4 Gy) given in 28 fractions Patients were treated with either 6 M Vor 15 MV photons The median overall treatment time was 39 elapsed days Toxicity during each week of irradiation was scored according to the RTOG acute toxicity criteria. All adverse events were scored, including skin toxicity, gastrointestinal effects, hematologic effects, and weight loss.
All patients signed an institutional informed consent form and were appraised of the expected acute and long term consequences of infusional 5-FU chemoradiation based on our experience using this technique in other sites [14, 23] .
Statistical methods
All patients were evaluated from the initiation of treatment until the last follow up or until death occurred. The data were analyzed with the WINKS 4.5 professional edition statistical package, survival curves were generated using the Kaplan-Meier method.
Results

Patients and methods
Between January 1997 and July 1999, 23 patients with ductal adenocarcinoma of the pancreas were treated in the University of Virginia Department of Radiation Oncology following surgical evaluation. Surgical readability was determined radiographically based on spiral CT and/or magnetic resonance imaging Six patients were deemed unresectable based on surgically staged blood vessel adherence discovered during laparotomy (n = 2). or on the basis of radiographic criteria showing vascular invasion or local tumor invasion precluding resection (n = 4). In seventeen others, chemoradiation was given postoperatively following pancreaticoduodenectomy (8 patients had pylorus sparing surgery). The median age of the 23 patients was 64 years (range 41-82) and there were 9 males and 14 females.
The American Joint Committee [1] (AJC) tumor staging of the 17 resected patients wasT| in 2.T 2 in I, and T, in 14. The primary tumor was pathologically confirmed to involve the head of the pancreas in 14 patients, the ampulla in 2. and the tail in 1 patient. In the 17 resected patients. 8 were node positive. 8 were node negative, and I was undetermined Thirteen patients had negative resection margins (R0). two had microscopic residual disease (Rl), and two had macroscopic residual disease (R2) Histologic examination of the surgical specimens showed lympho-vascular invasion in four patients and perineural invasion in six patients. The unresectable patients had AJC staged T, disease in five patients, and one patient was T4; three were node positive and in three the lymph node status was undetermined.
Twenty of twenty-three patients (87%) received 100% of the intended 5-FU dose. One patient (4%) had a dose reduction to 250 mg/m 2 /d and received only 94%. of the intended dose because of persistent nausea and vomiting. This female patient was briefly hospitalized and received intravenous fluids. Two other patients had their 5-FU discontinued because of a transient ischemic attack in one, and a myocardial infarction in another. Neither event was considered related to CIC therapy. These patients received 56% and 27% of their intended 5-FU doses, respectively. All patients received a minimum radiation dose of 50.4 Gy. Nineteen patients received 50.4 Gy, one received 52.2 Gy, one received 55.8 Gy and two received 59.4 Gy.
There was no RTOG grade 3 or 4 hematologic toxicity in any patient in this study. The principle acute complication was grade 2 nausea, which was well controlled with standard antiemetics. Weight loss as a percent of baseline varied, however no patient had weight loss of > 10%. No patient has developed RTOG grade 3 or 4 late toxicity.
Local control and survival
Treatment
All patients received concomitant chronomodulated infusional 5-FU chemotherapy during the entire course of external beam irradiation [23] . The prescribed 5-FU dose was 300 mg/m 2 /d given five days per week, Monday through Friday, with a median total dose of 8.4 grams (g)/m 2 (range 2.4-9.9 g/nr) Our chronomodulated technique uses a
Median follow-up for all patients is sixteen months, with a range of 4 to 41 months. The 6 patients treated for unresectable disease have a median survival of 13 months and 2 of 6 (33%) have tumor progression in the radiation treatment field.
Local failure was defined as any progression of dis- ease, as evidenced on follow-up abdominal CTor MRI scan. Five of seventeen (29%) patients in the resected group developed local-regional failure with a median time to failure of six months. The one-year actuarial survival is 88% for the 17 patients treated with post-operative adjuvant chemoradiation. The median survival of the 17 resected patients is 28 months.
Discussion
In the approximately 29,000 people in the US diagnosed annually with pancreatic adenocarcinoma, the hope of cure will be obtained in only a small minority. In 15% of patients fortunate to have a complete tumor resection, survival is only 6% to 24% at five years [19] . Novel strategies employing post-operative chemoradiation using combinations of chemotherapy and irradiation are being assessed but there is a growing concern regarding the acute toxicity associated with these programs. In this pilot study, we entertained the hypothesis that a relatively large volume of irradiated normal tissue could be spared acute toxicity of combined modality therapy by specifying precisely a time window to infuse the radiosensitizing chemotherapy. We became attracted to using a temporally dose dense infusion schedule based on the favorable toxicity profiles reported by others using chronomodulated infusional 5-FU technique. Improvement in treatment responses as well as in toxicity has been reported with this approach compared to standard bolus or infusional chemoradiation [10, 11] .
We have compared our chronomodulated infusion schedule with several large published series [3, 7, 8, 16, 21, 22, 24, 26, 28] (Table 2 ). For example, in comparison to the Stanford series of resected patients where a flat 5-FU infusion was used [16] , our chronomodulated approach delivered 16% more 5-FU (8.4 vs. 7.1 grams total dose of 5-FU delivered) and 13% more irradiation (51.2 vs. 45 Gy). We achieved this without increased acute or late toxicity and with fewer interruptions of irradiation. In another study, ECOG showed that a dose of 250 mg/m 2 /d for seven days/week could be given to patients with unresectable (22 of the 25 patients in the trial), residual, or resected pancreatic cancers [28] . Although their total 5-FU dose of 9.6 grams is higher than what we achieved, this difference may be related to their higher percentage of unresected patients that tolerate chemoradiation better than those treated postoperatively. Also, in the ECOG trial the dose limiting toxicity was mucositis, which was not observed in any other study. In the other trials summarized in Table 2 using bolus or flat infusional 5-FU chemoradiation, acute toxicity ranges between 10% to 15% and about the same proportion (~15%) necessitate hospitalization or require 5-FU dose reduction during the course of chemoradiation. In comparison, only 4% experienced grade 3 or 4 toxicity when treated with the chronomodulated approach. Furthermore, our patients' survival at one year of 88% (with a median follow-up of 16 months) is equivalent to that obtained with other more toxic 5-FU chemoradiation approaches.
In summary, this pilot study suggests there is less acute toxicity with chronomodulated infusional 5-FU chemoradiation compared to reports where there was no attempt to modulate the timing of administration of the systemic radiosensitizer. This approach should be examined further, especially with the use of newer combined modality therapy programs (e.g., camptothecins, gemcitabine) where acute toxicity is problematic.
